Stock ALXO ALX ONCOLOGY HOLDINGS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
16.86 USD -0.06% Intraday chart for ALX Oncology Holdings Inc. +8.08% +13.23%
04-18 Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing MT
04-10 ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing
ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept
ALX Oncology Holdings Inc. Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (?R/R B-NHL?)
ALX Oncology Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
ALX Oncology Holdings Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Top Midday Gainers
Sector Update: Health Care Stocks Advance Premarket Tuesday
ALX Oncology Q3 Net Loss Widens; Shares Ease After Hours
ALX Oncology Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
ALX Oncology Closes $63.2 Million Common Stock, Warrants Offering to Fund Clinical Development of Evorpacept
ALX Oncology Prices Underwritten Offering of Common Stock, Warrants for Expected Gross Proceeds of $55 Million
ALX Oncology Commences Common Stock, Warrants Offering to Fund Development of Evorpacept
Sector Update: Health Care Stocks Slipping Late Afternoon
Sector Update: Health Care
Top Midday Gainers
Investors Weigh Rising Bond Yields, Driving Premarket Losses for US Equity Futures
Top Premarket Gainers
ALX Oncology Holdings Inc. Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
ALX Oncology Holdings Names Jason Lettmann CEO
ALX Oncology Holdings Inc. Appoints Jason Lettmann as Chief Executive Officer
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALXO Stock
  4. News ALX Oncology Holdings Inc.
  5. Other languages